Cargando…
Development of antibody arrays for monoclonal antibody Higher Order Structure analysis
Antibody arrays were developed to probe a monoclonal antibody's three-dimensional structure (3-D structure). Peptides with overlapping regions were designed to cover the whole mAb light chain and heavy chain, respectively, and used to generate polyclonal antibodies after the conjugation of the...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3748713/ https://www.ncbi.nlm.nih.gov/pubmed/23970865 http://dx.doi.org/10.3389/fphar.2013.00103 |
_version_ | 1782281117472129024 |
---|---|
author | Wang, Xing Li, Qing Davies, Michael |
author_facet | Wang, Xing Li, Qing Davies, Michael |
author_sort | Wang, Xing |
collection | PubMed |
description | Antibody arrays were developed to probe a monoclonal antibody's three-dimensional structure (3-D structure). Peptides with overlapping regions were designed to cover the whole mAb light chain and heavy chain, respectively, and used to generate polyclonal antibodies after the conjugation of the peptides to a carrier protein, KLH. It was shown that good peptide specificity was achieved from the antibodies generated. Using more than 30 different polyclonal antibodies to measure the surface epitope distribution, it was shown that the mAb antibody array can detect epitope exposure as low as 0.1% of defined mAb populations. This ELISA-based analysis of mAb epitope exposure can be considered as a measurement of “conformational impurity” in biologics development, similar to the analysis of other product-related impurities such as different forms of glycosylation, deamidation, and oxidation. This analysis of “conformational impurity” could provide valuable information on the mAb conformational comparability for biosimilar mAbs as well as novel mAbs, especially in the area of protein immunogenicity. Furthermore, stability studies indicated that there are several conformational “hot spots” in many mAbs tested, especially in the hinge region. This antibody array technology can be used for novel mAb Higher Order Structure (HOS) analysis during process and formulation development. Another important area of application is for biosimilar mAb development where the innovator molecule and biosimilar molecule could be compared based on their systemic “fingerprint” from the 30 plus antibodies. |
format | Online Article Text |
id | pubmed-3748713 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-37487132013-08-22 Development of antibody arrays for monoclonal antibody Higher Order Structure analysis Wang, Xing Li, Qing Davies, Michael Front Pharmacol Pharmacology Antibody arrays were developed to probe a monoclonal antibody's three-dimensional structure (3-D structure). Peptides with overlapping regions were designed to cover the whole mAb light chain and heavy chain, respectively, and used to generate polyclonal antibodies after the conjugation of the peptides to a carrier protein, KLH. It was shown that good peptide specificity was achieved from the antibodies generated. Using more than 30 different polyclonal antibodies to measure the surface epitope distribution, it was shown that the mAb antibody array can detect epitope exposure as low as 0.1% of defined mAb populations. This ELISA-based analysis of mAb epitope exposure can be considered as a measurement of “conformational impurity” in biologics development, similar to the analysis of other product-related impurities such as different forms of glycosylation, deamidation, and oxidation. This analysis of “conformational impurity” could provide valuable information on the mAb conformational comparability for biosimilar mAbs as well as novel mAbs, especially in the area of protein immunogenicity. Furthermore, stability studies indicated that there are several conformational “hot spots” in many mAbs tested, especially in the hinge region. This antibody array technology can be used for novel mAb Higher Order Structure (HOS) analysis during process and formulation development. Another important area of application is for biosimilar mAb development where the innovator molecule and biosimilar molecule could be compared based on their systemic “fingerprint” from the 30 plus antibodies. Frontiers Media S.A. 2013-08-21 /pmc/articles/PMC3748713/ /pubmed/23970865 http://dx.doi.org/10.3389/fphar.2013.00103 Text en Copyright © 2013 Wang, Li and Davies. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Wang, Xing Li, Qing Davies, Michael Development of antibody arrays for monoclonal antibody Higher Order Structure analysis |
title | Development of antibody arrays for monoclonal antibody Higher Order Structure analysis |
title_full | Development of antibody arrays for monoclonal antibody Higher Order Structure analysis |
title_fullStr | Development of antibody arrays for monoclonal antibody Higher Order Structure analysis |
title_full_unstemmed | Development of antibody arrays for monoclonal antibody Higher Order Structure analysis |
title_short | Development of antibody arrays for monoclonal antibody Higher Order Structure analysis |
title_sort | development of antibody arrays for monoclonal antibody higher order structure analysis |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3748713/ https://www.ncbi.nlm.nih.gov/pubmed/23970865 http://dx.doi.org/10.3389/fphar.2013.00103 |
work_keys_str_mv | AT wangxing developmentofantibodyarraysformonoclonalantibodyhigherorderstructureanalysis AT liqing developmentofantibodyarraysformonoclonalantibodyhigherorderstructureanalysis AT daviesmichael developmentofantibodyarraysformonoclonalantibodyhigherorderstructureanalysis |